ビジネスモデル - 株式会社ジーエヌアイグループ

This page outlines GNI Group's business model, operating across four sectors: investment, pharmaceuticals, drug discovery, and medtech. The pharmaceutical division, Gyre Pharmaceuticals, develops and sells treatments for organ fibrosis, including an IPF drug in China. The drug discovery arm, Cullgen, employs proprietary uSMITE™ technology to degrade disease-related proteins, focusing on cancer, inflammation, and pain treatments. The medtech division, led by Berkeley Advanced Biomaterials and Berkeley Biologics, provides biocompatible materials with stable cash flows. The group pursues global growth through cross-border licensing, partnerships, and synergistic collaboration across all divisions.